Cargando…
Corrigendum to “Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery” [Drug Discov. Today 19 (2014), 171–182()
Autores principales: | Kell, Douglas B, Goodacre, Royston |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science Ltd. ;, Distributed by Virgin Mailing and Distribution
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617745/ https://www.ncbi.nlm.nih.gov/pubmed/28843314 http://dx.doi.org/10.1016/j.drudis.2014.03.019 |
Ejemplares similares
-
Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery()
por: Kell, Douglas B., et al.
Publicado: (2014) -
Corrigendum to “Rational approach to drug discovery for human schistosomiasis” [Int. J. Parasitol. Drugs Drug Resist. 16 (2021) 140–147]
por: LoVerde, Philip T., et al.
Publicado: (2022) -
The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives [Corrigendum]
Publicado: (2015) -
Metabolomics shows the way to new discoveries
por: Goodacre, Royston
Publicado: (2005) -
Corrigendum to “Preparing for the next pandemic: It is more than just about the numbers” [Clin. Imaging, 79, 2021 Nov, 179–182]
por: Thacker, Paul G., et al.
Publicado: (2022)